Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Managing Nausea on Mounjaro (tirzepatide for T2D): The HealthRX.com Step-by-Step Protocol

By
Published Updated Last reviewed
2 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Nausea at 5 / 10 / 15 mg / 12% / 15% / 18% vs 4% on placebo [1]
  • Any gastrointestinal adverse reaction / 37.1% / 39.6% / 43.6% vs 20.4% on placebo [1]
  • Stopped treatment for a GI reaction / 3.0% / 5.4% / 6.6% vs 0.4% on placebo [1]
  • When it clusters / During dose escalation; reports decreased over time [1]
  • Starting dose / 2.5 mg once weekly, then 2.5 mg steps at least 4 weeks apart [1]
  • Maximum dose / 15 mg weekly in adults; 10 mg in children 10 and older [1]
  • Kidney injury / Label links it to dehydration from GI reactions such as nausea, vomiting, diarrhea [1]
  • Abdominal pain to watch / Persistent or severe, sometimes radiating to the back, may signal pancreatitis [1]

How common is nausea on Mounjaro?

The label's pooled placebo-controlled data come from two trials in adults with type 2 diabetes, SURPASS-1 and SURPASS-5: 718 people took Mounjaro for a mean of 36.6 weeks [1]. Nausea was reported by 4% of the placebo group, 12% at 5 mg, 15% at 10 mg and 18% at 15 mg [1]. Diarrhea ran 9%, 12%, 13% and 17% across those same groups, vomiting 2%, 5%, 5% and 9%, and constipation 1%, 6%, 6% and 7% [1]. Decreased appetite was reported by 1% on placebo versus 5%, 10% and 11% [1].

Counting every gastrointestinal reaction together, 20.4% of placebo patients reported at least one versus 37.1% at 5 mg, 39.6% at 10 mg and 43.6% at 15 mg [1]. Treatment was stopped for a gastrointestinal reaction by 0.4% of the placebo group and by 3.0%, 5.4% and 6.6% of the 5, 10 and 15 mg groups [1]. Severe gastrointestinal reactions were uncommon: 0.9% on placebo, 1.3% at 5 mg, 0.4% at 10 mg and 1.2% at 15 mg [1].

These are Mounjaro's type 2 diabetes figures from two specific trials. The label cautions that adverse reaction rates from one drug's clinical trials cannot be directly compared with rates from another drug's trials and may not reflect rates observed in practice [1].

Gastric emptying and timing

Tirzepatide activates both the GIP and the GLP-1 receptor [1]. The label states that it delays gastric emptying, that this delay is largest after the first dose, and that it diminishes over time [1]. It also states that the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1].

The dose-escalation schedule

The label directs that the starting dose and escalation schedule be followed specifically to reduce the risk of gastrointestinal adverse reactions [1]. Mounjaro starts at 2.5 mg once weekly and rises in 2.5 mg steps after at least 4 weeks on the current dose, and only if additional glycemic control is needed; the maximum is 15 mg weekly in adults and 10 mg weekly in children 10 and older [1]. Each increase is tied both to a 4-week minimum and to a need for more glycemic control [1].

What has been tested for the nausea itself

Ginger has been studied for nausea in general, though not with tirzepatide. A 2015 review cited a systematic review of double-blind, placebo-controlled randomized trials that highlighted the potential efficacy of ginger for preventing and treating nausea and vomiting of various origins, while noting that additional controlled studies are needed; the review itself focused on pregnancy-related and chemotherapy-induced nausea [2].

We found no published study that tested an antiemetic such as ondansetron or metoclopramide, a specific eating plan, or a ginger product against tirzepatide-related nausea. The label's documented measure is the escalation schedule, and it also identifies symptoms that may signal a more serious problem [1].

What the label flags when nausea comes with something else

Dehydration and kidney injury. The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists including Mounjaro, with most events in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Pancreatitis. The label describes acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, and says to observe patients for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. The label says to discontinue Mounjaro if pancreatitis is suspected [1].

Gallbladder disease. Acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients in the adult placebo-controlled trials [1].

Severe gastrointestinal reactions. The label states that use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe, and that Mounjaro is not recommended in patients with severe gastroparesis [1].

Frequently asked questions

How long does nausea last after a Mounjaro injection?
The label reports that the majority of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. The label also says the delay in gastric emptying is largest after the first dose and diminishes over time [1].
Should I skip a Mounjaro dose if I feel nauseous?
The label says to follow its starting dosage and escalation schedule to reduce the risk of gastrointestinal adverse reactions [1]. Its missed-dose instruction is separate: if a dose is missed, give it as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip it and give the next dose on the regular day [1].
Is nausea a sign that Mounjaro is working?
The label lists nausea in the adverse reactions section, not as a measure of response [1]. The effects Mounjaro is approved for are improved glycemic control in type 2 diabetes, in adults and children 10 and older, and a lower risk of major cardiovascular events in adults with type 2 diabetes at high risk for them [1].
When is nausea on Mounjaro a sign of something more serious?
The label describes acute pancreatitis as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Mounjaro if pancreatitis is suspected [1]. It also reports acute gallbladder disease in 0.6% of Mounjaro-treated patients versus 0% on placebo, and postmarketing kidney injury from volume depletion, with most events in patients whose gastrointestinal reactions led to dehydration [1].
Does the injection site affect nausea?
Exposure to tirzepatide is similar whether the dose is injected into the abdomen, the thigh or the back of the upper arm, and the label advises rotating sites with each dose [1]. The upper arm site is for injection by another person [1]. We found no study comparing nausea by injection site.
Can I stay on a lower Mounjaro dose?
The Mounjaro label says to increase the dose in 2.5 mg increments after at least 4 weeks on the current dose only if additional glycemic control is needed [1]. In the label's pooled trials, nausea was 12% at 5 mg versus 18% at 15 mg [1].

References

  1. U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
  2. Giacosa A, Morazzoni P, Bombardelli E, Riva A, Bianchi Porro G, Rondanelli M. Can nausea and vomiting be treated with ginger extract?. Eur Rev Med Pharmacol Sci. 2015;19(7):1291-6. Can nausea and vomiting be treated with ginger extract?
Evidence overview for Managing Nausea on Mounjaro (tirzepatide for T2D): The HealthRX.com Step-by-Step Protocol